GSK Settles Two California Lawsuits Over Zantac Heartburn Drug

British pharmaceutical company GSK announced on Wednesday that it has agreed to settle two lawsuits in California related to its discontinued heartburn medication, Zantac, which plaintiffs claim caused cancer. Despite the settlements, GSK emphasized that it does not admit any liability in these cases.

Over the past year, GSK has faced multiple lawsuits regarding Zantac, with several of these cases originating in California—a state known for its challenging legal environment for multinational companies, as courts are often more favorable to plaintiffs.

GSK, along with former Zantac manufacturers Pfizer, Sanofi, and Boehringer Ingelheim, currently faces around 4,000 claims in California state courts, as well as approximately 2,000 lawsuits in other states across the U.S. However, the majority of the legal battles are taking place in Delaware, where GSK is defending itself against over 70,000 lawsuits.

In June, a judge in Delaware allowed these cases to proceed, a decision that was a setback for GSK. The drugmaker has since appealed, and last month, the Delaware Supreme Court agreed to hear the appeal, along with those from the other former Zantac manufacturers.

GSK #ZantacLawsuits #HeartburnDrug #CaliforniaSettlements #PharmaceuticalNews #ZantacLitigation #CancerClaims #LegalUpdate